作者
Prakhar Vijayvargiya, Zerelda Esquer Garrigos, Natalia E Castillo Almeida, Pooja R Gurram, Ryan W Stevens, Raymund R Razonable
发表日期
2020/7/1
来源
Mayo Clinic Proceedings
卷号
95
期号
7
页码范围
1454-1466
出版商
Elsevier
简介
The novel severe acute respiratory syndrome coronavirus 2 is causing a worldwide pandemic that may lead to a highly morbid and potentially fatal coronavirus disease 2019 (COVID-19). There is currently no drug that has been proven as an effective therapy for COVID-19. Several candidate drugs are being considered and evaluated for treatment. This includes clinically available drugs, such as chloroquine, hydroxychloroquine, and lopinavir/ritonavir, which are being repurposed for the treatment of COVID-19. Novel experimental therapies, such as remdesivir and favipiravir, are also actively being investigated for antiviral efficacy. Clinically available and investigational immunomodulators, such as the interleukin 6 inhibitors tocilizumab and sarilumab and the anti–granulocyte-macrophage colony-stimulating factor lenzilumab, are being tested for their anticipated effect in counteracting the pro-inflammatory cytokine …
引用总数
2020202120222023202433502193
学术搜索中的文章